M. Poudenx

3.7k total citations · 1 hit paper
41 papers, 1.7k citations indexed

About

M. Poudenx is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, M. Poudenx has authored 41 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 7 papers in Surgery. Recurrent topics in M. Poudenx's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (9 papers). M. Poudenx is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (9 papers). M. Poudenx collaborates with scholars based in France, United States and Italy. M. Poudenx's co-authors include Josiane Otto, Jérôme Mouroux, Nicolas Vénissac, Marius Ilié, Paul Hofman, Véronique Hofman, Catherine Butori, Charles‐Hugo Marquette, Salomé Lalvée and Élodie Long-Mira and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and JNCI Journal of the National Cancer Institute.

In The Last Decade

M. Poudenx

38 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

2015 459 citations Marius Ilié, Élodie Long-Mira et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Poudenx France	16	1.3k	1.1k	408	225	174	41	1.7k
Josiane Otto France	20	1.1k 0.9×	906 0.8×	259 0.6×	228 1.0×	204 1.2×	59	1.6k
Ke‐Neng Chen China	21	882 0.7×	1.0k 1.0×	334 0.8×	272 1.2×	155 0.9×	77	1.7k
M. Duruisseaux France	21	1.0k 0.8×	1.0k 0.9×	305 0.7×	413 1.8×	120 0.7×	105	1.6k
Myung‐Ju Ahn South Korea	20	792 0.6×	990 0.9×	139 0.3×	250 1.1×	159 0.9×	75	1.5k
A. Antón Spain	18	1.3k 1.0×	695 0.6×	492 1.2×	178 0.8×	179 1.0×	103	1.7k
Alice Chen United States	7	1.3k 1.0×	624 0.6×	221 0.5×	156 0.7×	332 1.9×	14	1.8k
Miso Kim South Korea	25	1.2k 0.9×	710 0.7×	208 0.5×	292 1.3×	95 0.5×	87	1.7k
Édith Borcoman France	17	948 0.7×	419 0.4×	170 0.4×	239 1.1×	152 0.9×	50	1.3k
Delphine Borchiellini France	22	986 0.8×	1.2k 1.1×	458 1.1×	639 2.8×	104 0.6×	89	1.8k
Ralf Wilkowski Germany	25	1.3k 1.0×	533 0.5×	524 1.3×	356 1.6×	108 0.6×	48	1.8k

Countries citing papers authored by M. Poudenx

Since Specialization

Citations

This map shows the geographic impact of M. Poudenx's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Poudenx with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Poudenx more than expected).

Fields of papers citing papers by M. Poudenx

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Poudenx. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Poudenx. The network helps show where M. Poudenx may publish in the future.

Co-authorship network of co-authors of M. Poudenx

This figure shows the co-authorship network connecting the top 25 collaborators of M. Poudenx. A scholar is included among the top collaborators of M. Poudenx based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Poudenx. M. Poudenx is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lassalle, Sandra, Véronique Hofman, Simon Heeke, et al.. (2020). Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France). Cancers. 12(4). 955–955. 17 indexed citations

Heeke, Simon, Véronique Hofman, Marius Ilié, et al.. (2020). Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution. Journal of Translational Medicine. 18(1). 87–87. 9 indexed citations

Hofman, Véronique, Jonathan Benzaquen, Simon Heeke, et al.. (2020). Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France). Lung Cancer. 145. 58–62. 12 indexed citations

Bouhlel, L., J. Doyen, Emmanuel Chamorey, et al.. (2020). Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bulletin du Cancer. 107(9). 946–958. 21 indexed citations

Heeke, Simon, Jonathan Benzaquen, Élodie Long-Mira, et al.. (2019). In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers. 11(9). 1271–1271. 26 indexed citations

Humbert, Olivier, Renaud Schiappa, M. Poudenx, et al.. (2019). 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. European Journal of Nuclear Medicine and Molecular Imaging. 47(5). 1158–1167. 61 indexed citations

Bondiau, Pierre‐Yves, M. Poudenx, Charlotte Cohen, et al.. (2019). Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer. BMC Cancer. 19(1). 305–305. 18 indexed citations

Levra, Matteo Giaj, Silvia Novello, Fausto Barbieri, et al.. (2017). P1.06-005 An International Cohort of Patients with Small Cell Lung Cancer after a Non-Small Cell Lung Carcinoma Oncogene or Non-Oncogene Addicted. Journal of Thoracic Oncology. 12(1). S667–S667.

Leduc, Charlotte, Hélène Blons, Benjamin Besse, et al.. (2016). Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Annals of Oncology. 27. vi416–vi416. 2 indexed citations

10.

Fiteni, Frédéric, Amélie Anota, Franck Bonnetain, et al.. (2016). Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. European Respiratory Journal. 48(3). 861–872. 14 indexed citations

11.

Ilié, Marius, Élodie Long-Mira, Coraline Bence, et al.. (2015). Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Annals of Oncology. 27(1). 147–153. 459 indexed citations breakdown →

12.

Bylicki, Olivier, Céline Ferlay, C. Chouaïd, et al.. (2013). Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study. Journal of Thoracic Oncology. 8(7). 906–914. 5 indexed citations

13.

Pérol, M., C. Chouaïd, David Pérol, et al.. (2012). Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(28). 3516–3524. 166 indexed citations

14.

Poudenx, M., Pierre‐Yves Bondiau, Emmanuel Chamorey, et al.. (2012). Cisplatin-Docetaxel Induction plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients: A Phase II Trial. Oncology. 83(6). 321–328. 9 indexed citations

15.

Marcy, Pierre‐Yves, et al.. (2011). An 11-cm Right Coronary Aneurysm Causing Heart Compression. Journal of the American College of Cardiology. 57(11). e99–e99. 1 indexed citations

16.

Hofman, Véronique, Christelle Bonnetaud, Marius Ilié, et al.. (2010). Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker. Clinical Cancer Research. 17(4). 827–835. 247 indexed citations

17.

Castelli, J., Juliette Thariat, Karen Bénézery, et al.. (2008). Analyse de la toxicité précoce des traitements par Cyberknife® des cancers pulmonaires et résultats préliminaires. Cancer/Radiothérapie. 12(8). 793–799. 12 indexed citations

18.

Leo, Francesco, Nicolas Vénissac, M. Poudenx, Josiane Otto, & Jérôme Mouroux. (2007). Multidisciplinary Management of Lung Cancer: How to Test Its Efficacy?. Journal of Thoracic Oncology. 2(1). 69–72. 87 indexed citations

19.

Mouroux, Jérôme, Nicolas Vénissac, Marco Alifano, Francesco Leo, & M. Poudenx. (2005). Combined Video-Assisted Mediastinoscopy and Thoracoscopy in the Management of Lung Cancer: A Five-Year Experience. Journal of Laparoendoscopic & Advanced Surgical Techniques. 15(5). 460–469. 4 indexed citations

20.

Pujol, Jean-Louis, Jean Pierre Daurès, Aart Brutel de la Rivière, et al.. (2001). Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study. JNCI Journal of the National Cancer Institute. 93(4). 300–308. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact